Short answer: both are engineered versions of insulin-like growth factor 1 (IGF-1) modified to dodge the IGF-binding proteins that normally restrain it. IGF-1 DES (Des(1–3) IGF-1) is truncated at the N-terminus — very short-acting, very locally potent. IGF-1 LR3 (Long R3 IGF-1) is extended and substituted — far longer half-life. Both are research reagents, both are banned in sport (WADA/USADA), and neither is approved for human use. This is educational, research-use-only information — not medical advice.
If you have searched IGF-1 DES vs IGF-1 LR3, you have found two of the most frequently confused entries in the growth-factor literature. They share a parent molecule and a design goal but behave very differently. This guide explains what each modification actually does, sets them side by side, and is honest about the regulatory and anti-doping reality that surrounds them.
Framing first. IGF-1 DES and IGF-1 LR3 are research compounds — recombinant proteins used in laboratory cell-culture and signalling studies. New-U does not sell them for human use and gives no dosing, performance or medical guidance. For the structural vocabulary, see amino acids vs peptides.
IGF-1 is a 70-amino-acid polypeptide hormone, structurally related to insulin, that mediates many of growth hormone’s downstream effects on cell growth and proliferation. In the body, the great majority of circulating IGF-1 is bound to a family of IGF-binding proteins (IGFBPs), which regulate its availability and half-life. Researchers engineer IGF-1 analogues precisely to evade those binding proteins, producing a reagent with more predictable, more potent activity in culture. A plain-English background on the IGF-1 hormone is given by Diet vs Disease.
IGF-1 DES is IGF-1 with the first three N-terminal amino acids (Gly-Pro-Glu) removed — hence “Des(1–3).” That small truncation dramatically lowers its affinity for IGFBPs, which the literature associates with high local potency but a very short duration of action. The recombinant protein is catalogued by laboratory-reagent suppliers including ProSpec (which reports purity >97% by RP-HPLC and SDS-PAGE), GoldBio, APExBIO and Novatein Biosciences.
IGF-1 LR3 takes the opposite design approach to duration. It adds a 13-amino-acid N-terminal extension (the “Long”) and substitutes arginine for glutamic acid at position 3 (the “R3”). Like DES, the R3 substitution reduces IGFBP binding — but the extension makes the molecule far more stable, giving it a substantially longer half-life. That is why LR3 is the more searched of the two (roughly an order of magnitude more search volume than DES) and the more commonly discussed in non-research contexts. A clinically framed risk-and-benefit discussion appears at HubMed Ed.
| IGF-1 DES (Des(1–3)) | IGF-1 LR3 (Long R3) | |
|---|---|---|
| Modification | First 3 N-terminal residues removed | 13-aa N-terminal extension + Arg³ substitution |
| IGFBP binding | Sharply reduced | Sharply reduced |
| Relative half-life | Very short (acute, local) | Much longer (extended) |
| Typical research framing | High local potency, transient signal | Sustained signalling exposure |
| Search interest | Lower (~720/mo US) | Higher (~6,600/mo US) |
| Regulatory status | Research reagent; not approved for human use; WADA-prohibited | |
Prohibited at all times. IGF-1 and its analogues sit in class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) of the WADA Prohibited List. The U.S. Anti-Doping Agency explains the listing in IGF-1 and the WADA Prohibited List, and the DoD’s Operation Supplement Safety bluntly confirms IGF-1: Is It Banned? — yes. Any competing athlete using IGF-1 DES or LR3 risks sanctions.
Beyond sport, regulators warn that growth-factor compounds are not benign. Australia’s Therapeutic Goods Administration covers the hazards of growth-hormone-axis compounds in “Too much of a good thing: health risks of human growth hormone.” IGF-1 signalling also intersects with cell-proliferation pathways that are studied in cancer biology — one reason these molecules are confined to controlled research settings. None of this is a reason to use them; it is the reason they are research-use-only.
For genuine laboratory work, the same diligence applies as to any reagent: a per-batch Certificate of Analysis with identity (mass spec) and purity (HPLC/SDS-PAGE), a verifiable supplier, and clean cold-chain handling. Research-reagent houses such as ProSpec, GoldBio and APExBIO above publish purity data; the wider research-vendor market — e.g. UK Peptides, Umbrella Labs, Pure Peptides UK and Pure Health Peptides — varies widely in documentation quality. Read how to choose a peptide supplier and how to read a CoA before you buy.
New-U does not sell IGF-1 DES or LR3. This guide is educational. If your research touches the GH/IGF axis, the compounds we do supply on the secretagogue side — for laboratory study only — include tesamorelin and the growth-hormone-releasing peptides discussed in the CJC-1295 / ipamorelin guide.
What is the difference between IGF-1 DES and LR3?
DES is truncated (Des(1-3)) and very short-acting; LR3 is extended + Arg³-substituted and long-acting. Both evade IGF-binding proteins.
Which is “stronger”?
The literature frames DES as more acutely, locally potent and LR3 as longer-lasting. They are not interchangeable, and neither is a recommendation - both are research reagents.
Is IGF-1 banned in sport?
Yes - WADA class S2, prohibited at all times; confirmed by USADA and OPSS.
Is it legal to buy?
As a research reagent, status depends on jurisdiction and how it is marketed; it is not approved for human use. See are peptides legal? This is not legal advice.
External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
New-U Research Compounds supplies sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a Certificate of Analysis. Research use only - not for human consumption.
Browse the catalog